Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | CYP2A13 | Q16696 | 8/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28802672 | 0.85 | HRH3 (0.43) | HTTHRH3MEN1ALDH1A1KMT2A | |
| SCHEMBL3070626 | 0.80 | KDM4E (0.51) | MEN1ALDH1A1KMT2ASMN1; SMN2NCF1 | |
| SCHEMBL3140167 | 0.76 | HRH3 (0.63) | HTTHRH3MEN1ALDH1A1KMT2A | |
| SCHEMBL8215515 | 0.73 | AR (0.43) | HTTALOX15HSD17B10MEN1ALDH1A1 | |
| SCHEMBL3145262 | 0.72 | NCF1 (0.52) | HTTHRH3ALDH1A1NCF1HPGD | |
| SCHEMBL14896784 | 0.71 | HTT (0.52) | HTTHRH3CYP2C9ALOX15HSD17B10 | |
| SCHEMBL60705 | 0.69 | HRH3 (0.66) | HRH3CYP2C9ALOX15HSD17B10MEN1 | |
| SCHEMBL2357269 | 0.69 | HTT (0.46) | HTTHRH3CYP2C9ALOX15HSD17B10 | |
| SCHEMBL15467001 | 0.69 | HRH3 (0.87) | HRH3CYP2C9ALOX15HSD17B10MEN1 | |
| SCHEMBL6277227 | 0.69 | OPRL1 (0.47) | CYP2C9HSD17B10MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106661019-A | Indolizine derivatives as phoshoinositide 3-kinases inhibitors | 奇斯药制品公司 | 2017-05-10 | — | — | CN | disclosed |
| US-20070208015-A1 | 5-Morpholinylmethylthiophenyl Pharmaceutical Compounds As P38 MAP Kinase Modulators | ASTEX THERAPEUTICS, LTD. (UK) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208015-A1 | 5-Morpholinylmethylthiophenyl Pharmaceutical Compounds As P38 MAP Kinase Modulators | MAPK1, MAPK3, MAPK10 | HTT 2328/4885HRH3 944/4885CYP2C9 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.